To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
General Information
DRAVP ID DRAVPe02091
Peptide Name S5
Sequence LNCYWPLNDYGFYTTTGIGYK
Sequence Length 21
UniProt ID None
Taxon ID None
Source Synthetic construct
Validation Experimentally Validated
Origin Information
Gene Name/ID Not Available
GenBank Not Available
Amino Acid position Not Available
Domain Accession ID Not Available
Nucleotide sequence ID Not Available
Molecular Type Not Available
Chromosomal Position Not Available
Activity Information
Target Organism SARS-CoV-2
Assay SARS-CoV-2 inhibition assay
Activity
Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry
Cytotoxicity No cytotoxicity information found in the reference(s) presented
Binding Target Not given
Mechanism All peptides (S2, S4, and S5) in this study bound to the ACE2 receptor and established a competitive inhibitory relationship with the RBD
Structure Information
PDB ID None
Predicted Structure Download No predicted structure available
Linear/Cyclic Linear
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Stereochemistry L
Physicochemical Information
Formula C118H161N25O33S1
Absent amino acids ARQEHMSVOU
Common amino acids Y
Mass 2489.78
Pl 5.83
Basic residues 1
Acidic residues 1
Hydrophobic residues 13
Net charge 0
Boman Index 0.55
Hydrophobicity -0.381
Aliphatic Index 55.71
Half Life
Extinction Coefficient cystines 11460
Absorbance 280nm 4.603
Polar residues 8
Literature Information
Literature 1
Title Peptide S4 is an entry inhibitor of SARS-CoV-2 infection
Pubmed ID 38917689
Reference Virology, 597, 110149.
Author Liang, Z., Wang, J., Zhang, H., Gao, L., Xu, J., Li, P., Yang, J., Fu, X., Duan, H., Liu, J., Liu, T., Ma, W., & Wu, K.
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.